Evidence map›Paper›PMID 27474121›Full record

ArticleThe Journal of allergy and clinical immunology2016

Clinical trial data access: Opening doors with TrialShare.

Adam L Asare, Vincent J Carey, Daniel Rotrosen, Gerald T Nepom

Abstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. ImmuneData: an integrated data discovery system for immunology data repositories.Database : the journal of biological databases and curation · 2022
    Pooled it
  2. Risk subgroups and intervention effects among infants at high risk for peanut allergy: A model for clinical decision making.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Adam L AsareImmune Tolerance Network, Bethesda, Md.
Vincent J CareyBrigham and Women's Hospital, Harvard Medical School, Boston, Mass.
Daniel RotrosenNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Gerald T NepomImmune Tolerance Network, Bethesda, Md; Benaroya Research Institute, Seattle, Wash. Electronic address: nepom@benaroyaresearch.org.

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
NIAID NIH HHS UM1 AI109565
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BiomarkersClinical Trials as TopicDatabase Management SystemsDatabases, FactualHumansImmune ToleranceInformation DisseminationStatistics as TopicBiomarkersclinical immunologyClinical trialsdata sharingimmune tolerance

Identifiers

PMID27474121
PMCPMC12425136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.